文献速递产科母胎医学

颈项透明层测量在首层NIPT时代早孕期超声筛查中的临床价值

Clinical Utility of Nuchal Translucency Measurement in First-Trimester Ultrasound Screening in a Setting With First-Tier NIPT for Aneuploidy Screening.
PubMed 文献 · Prenat Diagn · 2025-12-07

这项荷兰全国性前瞻队列研究纳入129,704例接受早孕期畸形筛查(FTAS)的孕妇,其中230例(0.18%)NT增厚(≥3.5 mm)并转诊至八家三级中心。NT增厚病例中33.9%检出结构或遗传异常,遗传异常中76.8%为染色体非整倍体、14.3%为SNV、8.9%为CNV,39.3%超出NIPT检测范围。结论认为在包含FTAS和NIPT的国家筛查项目中NT测量仍有附加价值。

要点

  • FTAS中NT增厚(≥3.5 mm)发生率为0.18%,其中33.9%检出异常。
  • NT增厚相关遗传异常中39.3%超出NIPT检测范围,NT测量可补充检出。
  • 未做NIPT而因NT增厚转诊者中29.3%诊断21/18三体,73.5%选择终止妊娠。

核心结论

  • 在包含FTAS和首层NIPT的国家筛查项目中,NT测量具有附加临床价值。
  • NT增厚病例的产前咨询应告知三体及其他遗传异常可作为FTAS异常的结果,尤其在拒绝NIPT时。

研究设计与样本

  • 全国性前瞻队列研究,为IMITAS研究中FTAS实施部分。
  • FTAS共129,704例,其中230例(0.18%)NT增厚。
  • 主要结局为基于产前和产后发现的 Structure 或遗传异常产前诊断。

主要发现

  • NT增厚病例中33.9%检出异常。
  • 遗传异常中76.8%为染色体非整倍体,14.3%为SNV,8.9%为CNV;39.3%超出NIPT检测范围。
  • 未做NIPT而因NT增厚转诊者中29.3%诊断21/18三体,其中73.5%选择终止妊娠。
  • 异常患病率随NT厚度增加而升高。

临床怎么用

  • 在首层NIPT筛查背景下仍应测量NT,以检出NIPT范围外的遗传异常及结构异常。
  • NT增厚转诊咨询应涵盖三体及其他遗传异常风险,尤其当孕妇拒绝NIPT时。

局限性

  • 仅纳入转诊至八家荷兰三级中心的NT增厚病例,未报告未转诊或失访情况。
  • 研究未设对照比较NT测量与否的检出差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the additional clinical value of nuchal translucency (NT) measurement at the first-trimester anomaly scan (FTAS) in a setting with first-tier non-invasive prenatal testing (NIPT). METHOD: This nationwide prospective cohort study, part of the IMITAS study on FTAS implementation, included all pregnancies with increased NT (≥ 3.5 mm) at FTAS, subsequently referred for detailed diagnostic scans at eight Dutch tertiary centers (Nov 2021-Nov 2022). Women with abnormal dating scans, abnormal NIPT before FTAS, or high-risk for fetal anomalies were not eligible for FTAS and received diagnostic ultrasound directly. The primary outcome was prenatal diagnosis of structural or genetic anomalies based on pre- and postnatal findings. RESULTS: FTAS was performed in 129,704 pregnancies, of which 230 (0.18%) had an increased NT. Anomalies were detected in 33.9% of these cases. Genetic anomalies included 76.8% aneuploidies, 14.3% SNVs, 8.9% CNVs; 39.3% beyond NIPT's detection scope. Trisomy 21/18 was diagnosed in 29.3% referred for increased NT without prior NIPT; 73.5% of these opted for termination. Anomaly prevalence increased with greater NT thickness. CONCLUSION: NT measurement adds value in a national screening program including FTAS and NIPT. Prenatal counseling should address trisomies and other genetic abnormalities as a potential result of an abnormal FTAS, particularly when NIPT is declined.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Lust EER, Bronsgeest K, Henneman L, et al. Clinical Utility of Nuchal Translucency Measurement in First-Trimester Ultrasound Screening in a Setting With First-Tier NIPT for Aneuploidy Screening. Prenat Diagn. 2025. PMID: 41353714. doi:10.1002/pd.70047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。